Genotyping of sequential post-progression plasma specimens reveals that treatment with sequential first-, second-, and third-generation ALK inhibitors can accelerate the accumulation of ALK resistance mutations and may lead to treatment-refractory compound ALK mutations. The selection for optimal first-line TKI is very important to achieve a more efficacious long-term strategy and prevent the emergence of on-target resistance. READ ARTICLE
Journal of Clinical Oncology DOI: 10.1200/JCO.2021.39.15_suppl.3011
Authors: Gang Hua, Xiaoxi Chen, Ruoying Yu, Hua Bao, Xue Wu and Yang Shao